Merck & Co. Inc. (MRK)

78.78
NYSE : Health Technology
Prev Close 78.78
Day Low/High 0.00 / 0.00
52 Wk Low/High 65.25 / 92.64
Avg Volume 10.77M
Exchange NYSE
Shares Outstanding 2.52B
Market Cap 198.85B
EPS 3.80
P/E Ratio 19.63
Div & Yield 2.44 (2.97%)
I Wouldn't Buy Pfizer Shares on This Pop

I Wouldn't Buy Pfizer Shares on This Pop

I would wait until the next down day, and there will be one.

Use DRIPs to Build a Socially Responsible Portfolio

Use DRIPs to Build a Socially Responsible Portfolio

Many quality companies that fit into the socially responsible investing camp offer direct-purchase plans, allowing investors an easy way to build an SRI portfolio.

Check Out These 2 Undervalued Drugmakers

Check Out These 2 Undervalued Drugmakers

I plan to add some additional exposure to each on the next 'hiccup' in the market using my usual covered call strategy.

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Jim Cramer: Are You a Star Player? Let's Put It to the Test

Do you know what a company does, does it do it well, and is there anything going on that could change the trajectory?

Here's My Take on Seattle Genetics

Here's My Take on Seattle Genetics

The firm is obviously fast becoming a real player in creating treatment for certain cancers. The firm still loses money.

Jim Cramer: Is the Day Where the Virus Ruled Our Lives Waning?

Jim Cramer: Is the Day Where the Virus Ruled Our Lives Waning?

That's the really good news about why we could bounce back so quickly from Thursday's debacle.

Warp Speed for 5 Vaccine Candidates, Watching KLA Corp, Trading Thoughts

Warp Speed for 5 Vaccine Candidates, Watching KLA Corp, Trading Thoughts

The administration will provide increased financial support to 5 pharmas working on Covid vaccines, and we must keep an eye on price action in this uncertain market.

Jim Cramer: This Is a Brave New Economy We're In

Jim Cramer: This Is a Brave New Economy We're In

The Fed and Treasury are set on avoiding the mistakes that doomed us in the past, and we have to invest for this new market we're in now.

Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

Arcturus Therapeutics Has a Candidate for a Covid-19 Vaccine

When I first started buying ARCT shares I didn't conceive of a valuation of $1 billion, but I also didn't conceive of the global impact of a pandemic.

China Headline Risk, Valuation Station and a Workday Play

China Headline Risk, Valuation Station and a Workday Play

WDAY looks ready to break out as traders weigh wether markets are now overbought after this 2-day run.

Equity-a-Palooza, Bank Stocks, Nasdaq 100 in the Red, Trading Thoughts

Equity-a-Palooza, Bank Stocks, Nasdaq 100 in the Red, Trading Thoughts

Rising U.S.-China tensions continue to weigh, but new home sales and stalled continuing jobless claims may be positive catalysts.

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

Jim Cramer: We Have a Rip Snorting Rally Unfathomable 2 Months Ago

So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.

Perception Continues to Drive the Market

Perception Continues to Drive the Market

The negatives are being shaken off like a first time rider on a long-time bull which means long remains the name of the game.

Merck Is All In With a Threefold Approach to Covid-19

Merck Is All In With a Threefold Approach to Covid-19

I've been long Merck for a long time, since way before this pandemic became part of our lives.

Merck's Languishing Charts Could Get Boost on New Covid-19 Initiatives

Merck's Languishing Charts Could Get Boost on New Covid-19 Initiatives

The drugmaker's technical signals have been lackluster of late, but news of these initiatives are giving its shares a lift.

This Chart Pattern Hints at a Bullish Future

This Chart Pattern Hints at a Bullish Future

The bullish reversal pattern is appearing not just in single names, but also in whole sectors.

Genprex Is Soaring - And There's a One Word Reason Why

Genprex Is Soaring - And There's a One Word Reason Why

The small biotech's market cap sits at $125 million, the low end of what I believe is fair.

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

Jim Cramer: Reopening Is Necessary, but Based on Little More Than Hope

It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.

Small-Caps Roar, Bets Against the Market, Trading Nvidia

Small-Caps Roar, Bets Against the Market, Trading Nvidia

Money movers are not buying protection for individual names, but they are starting to bet against the market en masse, while the Russell 2000 ran up 4% on Monday.

Jim Cramer: What to Buy and What to Sell Now, Part 2

Jim Cramer: What to Buy and What to Sell Now, Part 2

In the 2nd of a 3-part series, Jim Cramer goes through all 30 Dow stocks to evaluate what is safe to buy and what you should sell or avoid (like the plague).

Market Outflows, Unknown Earnings Expectations and Trading Notes: Market Recon

Market Outflows, Unknown Earnings Expectations and Trading Notes: Market Recon

Here are a number of things that I'm watching now.

Jim Cramer: Do You Really Want to Sell Now?

Jim Cramer: Do You Really Want to Sell Now?

The answer to that question depends on several factors, so let's break them down.

The Markets That Roared, China Trade, Travel Stocks Pain, Macy's Investor Day

The Markets That Roared, China Trade, Travel Stocks Pain, Macy's Investor Day

The timing of this morning's rally? Almost simultaneously news broke from both China and the UK of possible drugs to fight coronavirus.

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

Jim Cramer: 6 Stocks to Buy on Coronavirus Fears

These companies all could be strong -- even if the 2019 nCoV fear spreads.

Jim Cramer: I'm Dumbfounded Tesla's Stock Is Not Up Even More Than It Is

Jim Cramer: I'm Dumbfounded Tesla's Stock Is Not Up Even More Than It Is

This is a market that thrives on growth. Tesla has it in spades.

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

My Pick for 2020? You Won't Believe It's Been on Your Screen All Along

This company made headlines in 2019, and I'm betting on it as a great play -- in many senses of the word -- for this new year.

Personalis Has Struggled Since Its IPO - Here's How I'd Play It

Personalis Has Struggled Since Its IPO - Here's How I'd Play It

The company has a collaboration with Merck, and there are far worse partners you could have when working in the cancer segment of biotech.

Advanced Micro Devices Is a Real Player and Here's How I'm Trading It

Advanced Micro Devices Is a Real Player and Here's How I'm Trading It

I have long been enamored with Lisa Su as a Chief Executive.

2 Potential Targets as Biotech Acquisition Activity Heats Up

2 Potential Targets as Biotech Acquisition Activity Heats Up

TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.